Progyny, Inc. (PGNY) company profile
Close on Nov 13, 2026Market cap $2.78BP/E 33.2Yield –
About Progyny
Services-Misc Health & Allied Services, NEC, SIC 8090
Progyny provides specialized healthcare benefits management focused on fertility, family building, and women's health. The company offers employers customized benefits packages based on bundled treatment cycles that encompass clinical care, diagnostic testing, and advanced procedures. Its portfolio includes pharmacy benefit services for treatment-related medications, care navigation, and support programs spanning pregnancy, postpartum care, menopause, and parent wellbeing. Progyny primarily serves large employers across numerous private and public industries, contracting directly with organizations to manage comprehensive benefits for their workforces and dependents.
The company's operations extend throughout the United States, serving members across virtually all states through a provider network. This medical network includes over 1,190 specialists practicing across more than 690 clinic locations nationwide. Progyny contracts with more than 590 employers, covering approximately 7.2 million individuals. It also provides services internationally to meet country-specific requirements. The provided text does not state the company's headquarters.
Summary of the business section of Progyny's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Progyny, Inc.
- Founded
- 2008
- Headquarters
- New York, NY
- Address
- 1359 Broadway, 2nd Floor 10018
- Phone
- (212) 888-3124
- Website
- progyny.com
- Employees
- 856, Dec 31, 2025
- Industry
- Services-Misc Health & Allied Services, NEC
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, New York, NY
Stock & identifiers
- Ticker
- PGNY
- Exchange
- Nasdaq
- IPO date
- Oct 25, 2019
- Shares outstanding
- 77M, Jul 31, 2026
- Public float
- $1.90B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1551306
- CUSIP
- 74340E103
- ISIN
- US74340E1038
- FIGI
- BBG002H1K1H1
- Share class FIGI
- BBG002H1K1K7
- EIN
- 27-2220139
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David J. Schlanger | Executive Chairman, Director | 245,356 |
| Peter Anevski | CHIEF EXECUTIVE OFFICER, Director | 710,973 |
| Geoffrey Clapp | Chief Product Officer | 58,235 |
| Mark S. Livingston | CHIEF FINANCIAL OFFICER | 70,314 |
| Allison Swartz | EVP, GC | 83,976 |
| Melissa B. Cummings | Chief Operating Officer | 66,496 |
| Michael E. Sturmer | PRESIDENT | 255,205 |
| Kevin K. Gordon | Director | 33,319 |
| Cheryl Scott | Director | 34,439 |
| Lloyd H. Dean | Director | 26,519 |
| Elizabeth D. Bierbower | Director | 5,660 |
| Roger C. Holstein | Director | 28,729 |
| Debra L. Morris | Director | 5,660 |
| Jeffrey G. Park | Director | 39,981 |
| Norman Payson | Director | 343,712 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.22M | $10.34M | $2.15M | $61 | $136 |
| FY2024 | $1.36M | -$16.04M | $6.52M | $63 | $135 |
| FY2023 | $1.09M | $7.27M | $986.13K | $135 | $134 |
| FY2022 | $68.58M | $31.30M | $9.30M | $113 | $133 |
| FY2021 | $862.46K | $12.70M | $5.45M | $183 | $138 |
| FY2020 | $987.31K | $19.59M | $793.84K | $154 | $111 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Peter Anevski Chief Executive Officer | $870.00K | $3.50M | $2.10M | $736.89K | $13.75K | $7.22M | +430% |
| Mark Livingston Chief Financial Officer | $533.00K | $999.99K | $600.00K | $330.57K | $16.82K | $2.48M | +16% |
| Allison Swartz EVP, General Counsel and Secretary | $409.50K | $624.98K | $375.00K | $225.45K | $10.23K | $1.65M | -15% |
| Melissa Cummings Chief Operating Officer | $429.55K | $1.15M | $689.99K | $386.55K | $39.08K | $2.70M | – |
| Geoffrey Clapp Chief Product Officer | $336.46K | $749.98K | $450.00K | $226.53K | $9.67K | $1.77M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 25, 2019
- Offer price
- $13.00
- Securities offered
- 10,000,000
- Gross proceeds
- $130.00M
- Exchange
- Nasdaq
- First trading day
- Oct 25, 2019
- First-day close
- $15.94+22.6%
- Lock-up ends (est.)
- Apr 22, 2020
“The initial public offering price is $13.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 856 employees, of which 835 were full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 25, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 22, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 19, 2015 | Name change | Name changed from Auxogyn, Inc. to Progyny, Inc. |
See a number that looks wrong?